AU2014281398B2 - Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors - Google Patents
Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors Download PDFInfo
- Publication number
- AU2014281398B2 AU2014281398B2 AU2014281398A AU2014281398A AU2014281398B2 AU 2014281398 B2 AU2014281398 B2 AU 2014281398B2 AU 2014281398 A AU2014281398 A AU 2014281398A AU 2014281398 A AU2014281398 A AU 2014281398A AU 2014281398 B2 AU2014281398 B2 AU 2014281398B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- compounds
- further aspect
- mmol
- mao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LEDOBQJLDQMIJH-LPYMAVHISA-N C/C(/c1cc(Cl)ccc1O)=N\NC(c1cncc(S(N2CCN(C)CC2)(=O)=O)c1)=O Chemical compound C/C(/c1cc(Cl)ccc1O)=N\NC(c1cncc(S(N2CCN(C)CC2)(=O)=O)c1)=O LEDOBQJLDQMIJH-LPYMAVHISA-N 0.000 description 2
- 0 CC(C1=C(*)*C(*)C(C=O)=C1C)=C Chemical compound CC(C1=C(*)*C(*)C(C=O)=C1C)=C 0.000 description 2
- ATFNCVWMHFTCOK-UFWORHAWSA-N C/C(/c1cc(Cl)ccc1O)=N\NC(c(cc1Br)ccc1Cl)=O Chemical compound C/C(/c1cc(Cl)ccc1O)=N\NC(c(cc1Br)ccc1Cl)=O ATFNCVWMHFTCOK-UFWORHAWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/921,895 | 2013-06-19 | ||
| US13/921,895 US9266838B2 (en) | 2011-08-15 | 2013-06-19 | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| PCT/US2014/043179 WO2014205213A1 (en) | 2013-06-19 | 2014-06-19 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014281398A1 AU2014281398A1 (en) | 2016-01-21 |
| AU2014281398B2 true AU2014281398B2 (en) | 2018-10-04 |
Family
ID=52105283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014281398A Ceased AU2014281398B2 (en) | 2013-06-19 | 2014-06-19 | Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3010915B1 (enExample) |
| JP (1) | JP6525162B2 (enExample) |
| KR (1) | KR102288648B1 (enExample) |
| CN (2) | CN105555784B (enExample) |
| AU (1) | AU2014281398B2 (enExample) |
| BR (1) | BR112015032113B1 (enExample) |
| CA (1) | CA2915817C (enExample) |
| ES (1) | ES2739814T3 (enExample) |
| IL (1) | IL243200B (enExample) |
| MX (1) | MX366949B (enExample) |
| NZ (1) | NZ715331A (enExample) |
| SG (2) | SG10201710543PA (enExample) |
| WO (1) | WO2014205213A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105555784B (zh) * | 2013-06-19 | 2019-03-15 | 犹他大学研究基金会 | 作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016119031A1 (pt) * | 2015-01-29 | 2016-08-04 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| KR20180011331A (ko) | 2015-06-12 | 2018-01-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제와 관련된 바이오마커 및 그의 용도 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| KR20180099768A (ko) | 2015-12-30 | 2018-09-05 | 노파르티스 아게 | 증진된 효능을 갖는 면역 이펙터 세포 요법 |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| CA3021678A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| CN108727377A (zh) * | 2017-04-14 | 2018-11-02 | 四川大学 | 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途 |
| AU2018309372B2 (en) | 2017-08-03 | 2024-08-15 | Oryzon Genomics, S.A. | Methods of treating behavior alterations |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| CN108689960B (zh) * | 2018-06-07 | 2022-03-04 | 济南大学 | 5-苯亚甲基-2-苯基噻唑酮类化合物及其制备和应用 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| HRP20251471T1 (hr) | 2019-03-20 | 2026-01-02 | Oryzon Genomics, S.A. | Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat |
| SI3941466T1 (sl) | 2019-03-20 | 2026-04-30 | Oryzon Genomics, S.A. | Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| CN111471095B (zh) * | 2020-01-15 | 2021-12-21 | 上海众启生物科技有限公司 | 用于阿尔茨海默症自身抗体检测的含jmjd2d蛋白片段的组合物 |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| US20250275969A1 (en) | 2022-05-09 | 2025-09-04 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| US20260151399A1 (en) | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| CN116444437B (zh) * | 2023-03-08 | 2025-09-16 | 曲靖师范学院 | 抗癌医药达洛鲁胺的合成方法 |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
| WO2025188857A1 (en) * | 2024-03-05 | 2025-09-12 | University Of Florida Research Foundation, Incorporated | Hdac8 degraders and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120010075A1 (en) * | 2009-01-14 | 2012-01-12 | Dow Agrosciences Llc | Synergistic fungicidal compositions including hydrazone derivatives and copper |
| WO2013025805A1 (en) * | 2011-08-15 | 2013-02-21 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE472327T1 (de) * | 2005-01-07 | 2010-07-15 | Hoffmann La Roche | Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen |
| WO2006136008A1 (en) * | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| US20080214495A1 (en) * | 2005-07-08 | 2008-09-04 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| US9051296B2 (en) * | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| CA2727890A1 (en) * | 2010-01-13 | 2011-07-13 | Norbert Kartner | Compounds, compositions and treatments for v-atpase related diseases |
| AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| CN105555784B (zh) * | 2013-06-19 | 2019-03-15 | 犹他大学研究基金会 | 作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物 |
-
2014
- 2014-06-19 CN CN201480045891.0A patent/CN105555784B/zh not_active Expired - Fee Related
- 2014-06-19 ES ES14813387T patent/ES2739814T3/es active Active
- 2014-06-19 KR KR1020167001538A patent/KR102288648B1/ko not_active Expired - Fee Related
- 2014-06-19 SG SG10201710543PA patent/SG10201710543PA/en unknown
- 2014-06-19 EP EP14813387.9A patent/EP3010915B1/en not_active Not-in-force
- 2014-06-19 CN CN201910116764.XA patent/CN110015984A/zh active Pending
- 2014-06-19 AU AU2014281398A patent/AU2014281398B2/en not_active Ceased
- 2014-06-19 MX MX2015018032A patent/MX366949B/es active IP Right Grant
- 2014-06-19 WO PCT/US2014/043179 patent/WO2014205213A1/en not_active Ceased
- 2014-06-19 JP JP2016521574A patent/JP6525162B2/ja not_active Expired - Fee Related
- 2014-06-19 NZ NZ71533114A patent/NZ715331A/en not_active IP Right Cessation
- 2014-06-19 CA CA2915817A patent/CA2915817C/en active Active
- 2014-06-19 SG SG11201510376QA patent/SG11201510376QA/en unknown
- 2014-06-19 BR BR112015032113-5A patent/BR112015032113B1/pt not_active IP Right Cessation
-
2015
- 2015-12-17 IL IL243200A patent/IL243200B/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120010075A1 (en) * | 2009-01-14 | 2012-01-12 | Dow Agrosciences Llc | Synergistic fungicidal compositions including hydrazone derivatives and copper |
| WO2013025805A1 (en) * | 2011-08-15 | 2013-02-21 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015032113A2 (pt) | 2017-03-21 |
| KR102288648B1 (ko) | 2021-08-12 |
| EP3010915A1 (en) | 2016-04-27 |
| KR20160024929A (ko) | 2016-03-07 |
| SG11201510376QA (en) | 2016-01-28 |
| JP2016523256A (ja) | 2016-08-08 |
| CN105555784B (zh) | 2019-03-15 |
| SG10201710543PA (en) | 2018-02-27 |
| BR112015032113B1 (pt) | 2019-01-29 |
| CA2915817A1 (en) | 2014-12-24 |
| IL243200B (en) | 2020-10-29 |
| MX366949B (es) | 2019-07-30 |
| CN105555784A (zh) | 2016-05-04 |
| AU2014281398A1 (en) | 2016-01-21 |
| CA2915817C (en) | 2022-12-13 |
| NZ715331A (en) | 2019-09-27 |
| WO2014205213A1 (en) | 2014-12-24 |
| EP3010915B1 (en) | 2019-05-08 |
| MX2015018032A (es) | 2016-10-03 |
| ES2739814T3 (es) | 2020-02-04 |
| IL243200A0 (en) | 2016-02-29 |
| CN110015984A (zh) | 2019-07-16 |
| EP3010915A4 (en) | 2016-12-28 |
| JP6525162B2 (ja) | 2019-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3010915B1 (en) | Substituted (3-(5-chloro-2-hydroxyphenyl)-1-benzoyl-1h-pyrazole compounds as histone demethylase inhibitors | |
| EP2744330B1 (en) | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors | |
| US20170001970A1 (en) | Substituted benzohydrazide analogs as histone demethylase inhibitors | |
| US8569511B2 (en) | Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase | |
| US11142524B2 (en) | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | |
| US9642857B2 (en) | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors | |
| US20130345204A1 (en) | Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors | |
| NZ621078B2 (en) | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors | |
| US20200039956A1 (en) | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |